Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Alaunos Therapeutics
Tempus AI
Virginia Commonwealth University
M.D. Anderson Cancer Center
Pfizer
Stanford University
Columbia University
Five Prime Therapeutics, Inc.
Henry Ford Health System
Stanford University
pharmaand GmbH
University of Iowa
Xenetic Biosciences, Inc.
PharmaMar
Incyte Corporation
University of Chicago
Case Comprehensive Cancer Center
Mayo Clinic
Ipsen
Pfizer
UNC Lineberger Comprehensive Cancer Center
R-Pharm
M.D. Anderson Cancer Center
Novartis
University of Pittsburgh